To improve psoriatic arthritis outcomes, address common comorbiditiesMarch 12, 2021Psoriatic ArthritisPsoriasis
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2bFebruary 10, 2021PsoriasisPsoriatic Arthritis
Synovial, skin gene expression differences may explain PsA treatment responsesDecember 11, 2020Psoriatic ArthritisPsoriasis
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritisNovember 30, 2020Psoriatic ArthritisPsoriasis
Psoriasis, PsA, and pregnancy: Tailoring treatment with increasing dataSeptember 2, 2020PsoriasisPsoriatic Arthritis
Doctors hesitated to embrace biosimilar infliximab in first 2 yearsJuly 20, 2020Psoriatic ArthritisPsoriasis
Clinicians address psoriatic disease risk in the era of COVID-19July 17, 2020PsoriasisPsoriatic Arthritis
Biologics yield low rates of skin clearance in real-world psoriasis studyJune 3, 2020PsoriasisPsoriatic Arthritis
Genome study examines heritability of psoriatic disease subtypesApril 2, 2020Psoriatic ArthritisPsoriasis
Rapid shift to adalimumab biosimilars in Denmark contrasts with U.S. experienceMarch 31, 2020Psoriatic ArthritisPsoriasis
Psoriasis Therapy During the COVID-19 Pandemic: Should Patients Continue Biologics? March 23, 2020PsoriasisPsoriatic Arthritis
